Literature DB >> 12634614

Metabolism of paclitaxel in mice.

Heleen A Bardelmeijer1, Ingrid A M Oomen, Michel J X Hillebrand, Jos H Beijnen, Jan H M Schellens, Olaf van Tellingen.   

Abstract

Previous mass balance studies in humans and mice have shown that the fecal and urinary recovery of paclitaxel and known metabolites (3' -hydroxypaclitaxel, 6alpha-hydroxypaclitaxel and 3',6alpha-dihydroxypaclitaxel) was not complete. Obviously this discrepancy is caused by the existence of other yet unknown metabolites. Mdr1a/1b(-/-) mice excrete very low quantities of unchanged paclitaxel. We have therefore used these mice receiving i.v. [3H]paclitaxel to further study the metabolic fate of paclitaxel. The major part of the radiolabel, being 70%, was excreted in the feces. A lipophilic sample, containing about 70% of the radioactivity present in the feces sample, was obtained by diethyl ether extraction. The aqueous residue containing about 30% of the radioactivity was further extracted using methanol. The high-performance liquid chromatography (HPLC) chromatograms of the lipophilic and aqueous sample revealed two and five putative new metabolites of paclitaxel, respectively. The HPLC fractions containing substantial amounts of radioactivity were subjected to tandem mass spectrometry. Two novel monohydroxylated paclitaxel structures were identified, which are probably 2m-hydroxypaclitaxel and 19-hydroxypaclitaxel, structures previously identified in rats. Including these metabolites, about 60% of the mass balance of paclitaxel could be quantified. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634614     DOI: 10.1097/00001813-200303000-00003

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

1.  Formulating paclitaxel in nanoparticles alters its disposition.

Authors:  Teng Kuang Yeh; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

2.  Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.

Authors:  Xinghe Wang; Gang Zhao; Sang Van; Nan Jiang; Lei Yu; David Vera; Stephen B Howell
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-11       Impact factor: 3.333

3.  Limited Impact of Murine Placental MDR1 on Fetal Exposure of Certain Drugs Explained by Bypass Transfer Between Adjacent Syncytiotrophoblast Layers.

Authors:  Arimi Fujita; Saki Noguchi; Rika Hamada; Satoko Inoue; Tsutomu Shimada; Satomi Katakura; Tetsuo Maruyama; Yoshimichi Sai; Tomohiro Nishimura; Masatoshi Tomi
Journal:  Pharm Res       Date:  2022-01-26       Impact factor: 4.580

4.  Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.

Authors:  V Vassileva; E H Moriyama; R De Souza; J Grant; C J Allen; B C Wilson; M Piquette-Miller
Journal:  Br J Cancer       Date:  2008-11-25       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.